We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
News

Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim

Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
News

Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million.

The compound, which was discovered and optimized within the alliance, is being developed as a novel treatment for neuropathic pain, a disease caused by damage or dysfunction of the nervous system and affecting up to 7-8% of the world’s population.

The alliance has involved working on multiple high priority targets across key therapeutic areas and has recently been expanded for four further years to include oncology. So far it has resulted in eight milestone payments from multiple programmes.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “This clearly validates our strategy of creating value for our partners and further emphasises our expertise in providing most efficient integrated drug discovery solutions for our collaborators. We are looking forward to advancing other exciting projects towards the clinic as part of this innovative alliance.”
Advertisement